Value-based prescription drug pricing agreements are increasing for many expensive and complex drugs. However, these agreements are becoming less used for some less complicated drugs. Understanding the underlying factors leading to this agreement using analytics software, among other tools, can provide important information when it comes to market access during the COVID-19 pandemic.
“Understanding market access is hard. Tracking shifts in coverage and payer policies for your brand and competitive brands is even harder. MMIT Analytics delivers comprehensive formulary, medical policy and restriction information and the software tools to put that analysis to work for your brand. Whether you are launching a product or managing an established brand in your disease area, understanding market access and payer coverage is critical.” Learn more here.
(Source: MMIT, 2021)